摘要
目的:确定是否(1)血浆淀粉样蛋白β之间存在一种关系(Aβ)1 - 40和1-42肽水平,老年人与非遗忘型轻度认知功能损害的脑容积和认知能力(aMCI),(2)血浆Aβ肽水平在不同载脂蛋白E(APOE)ε4携带者和非携带者和(3)纵向变化的认知和大脑体积与Aβ水平相关。方法:伴随aMCI 的受试者(n = 89)与正常认知(N = 126)分别来自Sydney记忆和老龄化研究(Sydney MAS),以非痴呆人群70-90岁的为基础个体研究;39位阿尔茨海默氏病(AD)患者从专业诊所被招募。Sydney MAS参与者接受脑部核磁共振成像扫描,并被19种认知措施评估和ApoE基因ε4。等离子体水平的Aβ1-40使用ELISA和1-42量化。结果:Aβ多肽的WAVE1的血浆水平和 Aβ1−42/1-40比率在AD和aMCI 中比例较低,并且Aβ1−42与全球认知及海马体积呈负相关的白质高信号呈负相关。一个 Aβ1-40和 Aβ1-42的关系主要是分别观察ε4等位基因携带者和非携带者。纵向分析显示在全球认知和记忆更大的跌幅对Aβ1−42的最高昆泰和比率测量。结论:血浆β水平和一个 Aβ1−42 / 1比是认知及海马体积有关,与一个 Aβ1-40和 Aβ1-42在ε4携带者和非携带者微分关系。这些数据支持AD病理学Aβ模型,并表明等离子体Aβ措施可以作为生物标志物。
关键词: Aβ1-40、 Aβ1-42、APOE、脑体积、认知、神经心理学测试、MRI、血浆、白质高信号。
Current Alzheimer Research
Title:The Relationship Between Plasma Aβ Levels, Cognitive Function and Brain Volumetrics: Sydney Memory and Ageing Study
Volume: 13 Issue: 3
Author(s): Anne Poljak, John D. Crawford, George A. Smythe, Henry Brodaty, Melissa J. Slavin, Nicole A. Kochan, Julian N. Trollor, Wei Wen and Karen A. Mather, Amelia A. Assareh, Pek C. Ng, Perminder S. Sachdev
Affiliation:
关键词: Aβ1-40、 Aβ1-42、APOE、脑体积、认知、神经心理学测试、MRI、血浆、白质高信号。
摘要: Objectives: Determine whether (1) a relationship exists between plasma amyloid-β (Aβ)1- 40 and 1-42 peptide levels, brain volumetrics and cognitive performance in elderly individuals with and without amnestic mild cognitive impairment (aMCI), (2) plasma Aβ peptide levels differ between apolipoprotein E (APOE) ε4 carriers and non-carriers and (3) longitudinal changes in cognition and brain volume relate to Aβ levels. Methods: Subjects with aMCI (n = 89) and normal cognition (n = 126) were drawn from the Sydney Memory and Aging Study (Sydney MAS), a population based study of non-demented 70-90 year old individuals; 39 Alzheimer’s disease (AD) patients were recruited from a specialty clinic. Sydney MAS participants underwent brain MRI scans and were assessed on 19 cognitive measures and were APOE ε4 genotyped. Plasma levels of Aβ1-40 and 1-42 were quantified using ELISA. Results: Wave1 plasma levels of Aβ peptides and Aβ1−42/1-40 ratio were lower in aMCI and AD, and Aβ1−42 was positively associated with global cognition and hippocampal volume and negatively with white matter hyperintensities. The relationships of Aβ1-40 and Aβ1-42 were predominantly observed in ε4 allele carriers and non-carriers respectively. Longitudinal analysis revealed greater decline in global cognition and memory for the highest quintiles of Aβ1−42 and the ratio measure. Conclusion: Plasma Aβ levels and the Aβ1−42/1-40 ratio are related to cognition and hippocampal volumes, with differential associations of Aβ1-40 and Aβ1-42 in ε4 carriers and non-carriers. These data support the Aβ sink model of AD pathology, and suggest that plasma Aβ measures may serve as biomarkers of AD.
Export Options
About this article
Cite this article as:
Anne Poljak, John D. Crawford, George A. Smythe, Henry Brodaty, Melissa J. Slavin, Nicole A. Kochan, Julian N. Trollor, Wei Wen and Karen A. Mather, Amelia A. Assareh, Pek C. Ng, Perminder S. Sachdev , The Relationship Between Plasma Aβ Levels, Cognitive Function and Brain Volumetrics: Sydney Memory and Ageing Study, Current Alzheimer Research 2016; 13 (3) . https://dx.doi.org/10.2174/1567205013666151218150202
DOI https://dx.doi.org/10.2174/1567205013666151218150202 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Alzheimer's Disease Drug Development
Alzheimer's disease is a progressive neurodegenerative disorder that affects millions of people worldwide. Despite decades of research, no cure or disease-modifying treatment is available yet. Therefore, the need for developing effective therapies to treat Alzheimer's disease is an urgent matter. This special issue aims to provide a comprehensive overview of ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Environment, Physical Activity, and Neurogenesis: Implications for Prevention and Treatment of Alzhemiers Disease
Current Alzheimer Research Inflammaging and Proteases in Abdominal Aortic Aneurysm
Current Vascular Pharmacology Neurodegenerative Disease: A Perspective on Cell-Based Therapy in the New Era of Cell-Free Nano-Therapy
Current Pharmaceutical Design T Cell Replicative Senescence in Human Aging
Current Pharmaceutical Design New Tracers and New Perspectives for Molecular Imaging in Lewy Body Diseases
Current Medicinal Chemistry Potential Therapeutic Targeting of Platelet-Mediated Cellular Interactions in Atherosclerosis and Inflammation
Current Medicinal Chemistry Possible Role of Vascular Risk Factors in Alzheimer's Disease and Vascular Dementia
Current Pharmaceutical Design Beneficial Actions of Polyunsaturated Fatty Acids in Cardiovascular Diseases: But, How and Why?
Current Nutrition & Food Science Cytochrome P450 Drug Metabolizing Enzymes in Roma Population Samples: Systematic Review of the Literature
Current Medicinal Chemistry Genetic Studies of Type 2 Diabetes in South Asians: A Systematic Overview
Current Diabetes Reviews Brain Network Connectivity Mediates Education-related Cognitive Performance in Healthy Elderly Adults
Current Alzheimer Research State-of-the-Art Lentiviral Vectors for Research Use: Risk Assessment and Biosafety Recommendations
Current Gene Therapy Obesity Promotes Oxidative Stress and Exacerbates Sepsis-induced Brain Damage
Current Neurovascular Research The Metabolic Syndrome and HIV Infection
Current Pharmaceutical Design Chemical and Pharmacological Significance of Natural Guanidines from Marine Invertebrates
Mini-Reviews in Medicinal Chemistry Uric Acid in Metabolic and Cerebrovascular Disorders: A Review
Current Vascular Pharmacology Blurred Edges: Evolving Concepts of Autism Spectrum Disorders and Schizophrenia
Adolescent Psychiatry P2Y Purinoceptors as Potential Emerging Therapeutical Target in Vascular Disease
Current Pharmaceutical Design Poly(ADP-Ribose) Polymerase Inhibitors: New Pharmacological Functions and Potential Clinical Implications
Current Pharmaceutical Design Angiotensin-Receptor Blockers and the Risk of Alzheimer´s Disease: A Meta-analysis
Current Reviews in Clinical and Experimental Pharmacology